VBI Vaccines Inc
OTC:VBIVQ

Watchlist Manager
VBI Vaccines Inc Logo
VBI Vaccines Inc
OTC:VBIVQ
Watchlist
Price: 0.0005 USD Market Closed
Market Cap: $14.3k

Operating Margin

-767%
Current
Improving
by 2 573.3%
vs 3-y average of -3 340.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-767%
=
Operating Income
$-72.2m
/
Revenue
$9.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-767%
=
Operating Income
$-72.2m
/
Revenue
$9.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
VBI Vaccines Inc
NASDAQ:VBIV
808.8k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 92% of companies in the United States of America
Percentile
8th
Based on 14 112 companies
8th percentile
-767%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

VBI Vaccines Inc
Glance View

Market Cap
14.3k USD
Industry
Biotechnology

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 149 full-time employees. The company went IPO on 2001-11-19. The firm develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers including glioblastoma (GBM). Its PreHevbrio (Hepatitis B Vaccine [Recombinant]), which contains S, pre-S2, and pre-S1 HBV surface antigens and is an approved 3-antigen HBV vaccine for adults. Its Prophylactic candidates include VBI-2900, which is a coronavirus vaccine Program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901, which targets CMV proteins present in tumor cells. The firm is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901.

VBIVQ Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-767%
=
Operating Income
$-72.2m
/
Revenue
$9.4m
What is VBI Vaccines Inc's current Operating Margin?

The current Operating Margin for VBI Vaccines Inc is -767%, which is above its 3-year median of -3 340.4%.

How has Operating Margin changed over time?

Over the last 3 years, VBI Vaccines Inc’s Operating Margin has increased from -5 308.5% to -767%. During this period, it reached a low of -14 837% on Mar 31, 2022 and a high of -637.1% on Dec 31, 2023.

Back to Top